Author(s): Weir RA, Chong KS, Dalzell JR, Petrie CJ, Murphy CA,
Abstract Share this page
Abstract AIMS: Apelin, a novel peptide with a putative role in cardiovascular homeostasis, has gained interest as an endogenous inotrope, but has yet to be described following acute myocardial infarction (AMI) in man. We aimed to characterize plasma apelin concentrations following AMI and to examine its relationship with clinical and prognostic biomarkers. METHODS AND RESULTS: Plasma concentrations of apelin, N-terminal probrain natriuretic peptide (NT-proBNP), norepinephrine, and arginine vasopressin were measured in 100 patients [mean age 58.9 +/- 12 (SD) years, 77\% male] admitted with AMI, with echocardiographic left ventricular (LV) ejection fraction <40\%, at mean 46 h after admission and at 24 weeks. Cardiac magnetic resonance imaging was performed pre-discharge and at 24 weeks. Thirty-eight subjects with no cardiac history acted as controls. Apelin concentration was reduced early after AMI (0.54 +/- 0.25 vs. 3.22 +/- 3.01 ng/mL, P <0.001) and remained low at 24 weeks, although it did increase significantly from baseline to 0.62 +/- 0.36 ng/mL, P = 0.030. Apelin had no relationship with any parameter of LV function over time. A relationship was found between baseline apelin and norepinephrine (r = 0.26, P = 0.008). Both NT-proBNP and norepinephrine correlated with adverse ventricular function after AMI. CONCLUSION: Plasma apelin concentration is reduced early after AMI, increases significantly over time, but remains depressed at 24 weeks. TRIAL REGISTRATION: ClinicalTrials.gov NCT00132093.
This article was published in Eur J Heart Fail
and referenced in Journal of Clinical & Experimental Cardiology